Abstract
In the past two decades a large initiative has been put forth to understand the biological and pathogenic properties of the human T-cell lymphotropic virus type 1 (HTLV-1); this has ultimately led to the development of various experimental vaccination and therapeutic strategies to combat HTLV-1 infection. The focus of this work is to outline key targets for the design of therapeutics for HTLV-1, such as fusion mediated by the envelope glycoprotein, and to discuss reports of novel vaccines or therapeutics. These strategies include peptide, recombinant protein, DNA, and viral vectors. The final focus of this review is to acquaint the reader with vaccine approaches developed in our laboratory over the last decade. These strategies include the development of envelope glycoprotein derived B-cell epitopes for the induction of neutralizing antibodies, as well as a strategy to generate a multivalent cytotoxic T-lymphocyte (CTL) response against the HTLV-1 Tax antigen.
Keywords: central nervous system, envelope glycoprotein (Env), epitopes, Cytotoxic T-cells, Immunization, Tetanus toxoid
Current Protein & Peptide Science
Title: Advances in HTLV-1 Peptide Vaccines and Therapeutics
Volume: 7 Issue: 2
Author(s): Marcus P. Lynch and Pravin T.P. Kaumaya
Affiliation:
Keywords: central nervous system, envelope glycoprotein (Env), epitopes, Cytotoxic T-cells, Immunization, Tetanus toxoid
Abstract: In the past two decades a large initiative has been put forth to understand the biological and pathogenic properties of the human T-cell lymphotropic virus type 1 (HTLV-1); this has ultimately led to the development of various experimental vaccination and therapeutic strategies to combat HTLV-1 infection. The focus of this work is to outline key targets for the design of therapeutics for HTLV-1, such as fusion mediated by the envelope glycoprotein, and to discuss reports of novel vaccines or therapeutics. These strategies include peptide, recombinant protein, DNA, and viral vectors. The final focus of this review is to acquaint the reader with vaccine approaches developed in our laboratory over the last decade. These strategies include the development of envelope glycoprotein derived B-cell epitopes for the induction of neutralizing antibodies, as well as a strategy to generate a multivalent cytotoxic T-lymphocyte (CTL) response against the HTLV-1 Tax antigen.
Export Options
About this article
Cite this article as:
Lynch P. Marcus and Kaumaya T.P. Pravin, Advances in HTLV-1 Peptide Vaccines and Therapeutics, Current Protein & Peptide Science 2006; 7 (2) . https://dx.doi.org/10.2174/138920306776359803
DOI https://dx.doi.org/10.2174/138920306776359803 |
Print ISSN 1389-2037 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5550 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Melamine Derivatives - A Review on Synthesis and Application
Current Organic Synthesis The Interplay between the Gut Immune System and Microbiota in Health and Disease: Nutraceutical Intervention for Restoring Intestinal Homeostasis
Current Pharmaceutical Design How Much of the Proteome Do We See with Discovery-Based Proteomics Methods and How Much Do We Need to See?
Current Proteomics Ovarian Cancer Biomarkers: Headway Towards Early Diagnosis
Current Chemical Biology Sinonasal Carcinoma: Updated Phenotypic and Molecular Characterization
Current Cancer Therapy Reviews Medical Applications of Hyperthermia Based on Magnetic Nanoparticles
Recent Patents on Biomedical Engineering (Discontinued) Multicolor-FISH Approaches for the Characterization of Human Chromosomes in Clinical Genetics and Tumor Cytogenetics
Current Genomics ACE2 as a Key Target for Treatment of COVID-19 Related Cardiovascular Diseases: Current Progress and Prospect
Current Drug Targets Oncomirs: From Tumor Biology to Molecularly Targeted Anticancer Strategies
Mini-Reviews in Medicinal Chemistry Effect of DNA Repair Deficiencies on the Cytotoxicity of Drugs Used in Cancer Therapy - A Review
Current Medicinal Chemistry Metastatic Breast Cancer, Organotropism and Therapeutics: A Review
Current Cancer Drug Targets A Computer - Aided Drug Designing for Pharmacological Inhibition of Mutant ALK for the Treatment of Non-small Cell Lung Cancer
Current Topics in Medicinal Chemistry Role of mTOR in Hematological Malignancies
Current Cancer Therapy Reviews Inhibition of Apoptosis in Pediatric Cancer by Survivin
Current Pediatric Reviews Acute Hypersensitivity Reactions to Chemotherapy Agents: An Overview
Inflammation & Allergy - Drug Targets (Discontinued) Understanding Tumor-Antigen Presentation in the New Era of Cancer Immunotherapy
Current Pharmaceutical Design Phosphodiesterase Inhibition as a Therapeutic Target for Brain Ischemia
CNS & Neurological Disorders - Drug Targets Natural Products, Synthetic and Non-Nucleoside Compounds as Inhibitors of Enzymes Related to DNA: Update 2013
Current Enzyme Inhibition Editorial (Thematic Issue: Thyroid Hormones. From Molecular Signaling to Human Disease: An Update)
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Withdrawal Notice: Role, Significance and Association of microRNA-10a/b in Physiology of Cancer
MicroRNA